Last reviewed · How we verify
Peg-IFN α-2b combined with NAs
Pegylated interferon alpha-2b combined with nucleos(t)ide analogues works by enhancing immune response against hepatitis B virus while simultaneously inhibiting viral replication.
Pegylated interferon alpha-2b combined with nucleos(t)ide analogues works by enhancing immune response against hepatitis B virus while simultaneously inhibiting viral replication. Used for Chronic hepatitis B infection (HBeAg-positive or HBeAg-negative), HBV with compensated liver disease.
At a glance
| Generic name | Peg-IFN α-2b combined with NAs |
|---|---|
| Sponsor | Shenzhen Third People's Hospital |
| Drug class | Interferon alpha combined with nucleos(t)ide reverse transcriptase inhibitor |
| Target | Interferon-alpha receptor (IFNAR); HBV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | FDA-approved |
Mechanism of action
Peg-IFN α-2b is a long-acting interferon that activates innate and adaptive immune responses to clear HBV-infected hepatocytes. Nucleos(t)ide analogues (NAs) such as lamivudine, entecavir, or tenofovir directly inhibit HBV reverse transcriptase, suppressing viral replication. The combination approach leverages both immune activation and direct antiviral activity to achieve sustained virological response and HBeAg/HBsAg clearance.
Approved indications
- Chronic hepatitis B infection (HBeAg-positive or HBeAg-negative)
- HBV with compensated liver disease
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Hematologic toxicity (neutropenia, thrombocytopenia)
- Psychiatric effects (depression, anxiety)
- Thyroid dysfunction
- Injection site reactions
- Headache
Key clinical trials
- A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs (PHASE2)
- Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study
- Clinical Efficacy of Pegylated Interferon Alpha-2b Combined With Nucleos(t)Ide Analogues in the Treatment of Chronic Hepatitis B Patients (PHASE4)
- Efficacy of NA Combined With PEG-IFN-α2b in the Continuous Versus Pulsed Treatment of Patients With Chronic Hepatitis B (EARLY_PHASE1)
- A Clinical Trial on HB-Vac Activated-DCs Combined With Peg-IFN or NAs in CHB (PHASE1, PHASE2)
- Combination Treatment of NAs and Peg IFN α-2b for Hepatitis B Related, Compensatory Cirrhosis Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Peg-IFN α-2b combined with NAs CI brief — competitive landscape report
- Peg-IFN α-2b combined with NAs updates RSS · CI watch RSS
- Shenzhen Third People's Hospital portfolio CI